Back

Real-world eligibility and cost-effectiveness analysis for empagliflozin in patients with heart failure

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Chronic heart failure - Pharmacotherapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Eui-Soon Kim

Seoul St. Marys Hospital, Seoul (Korea (Republic of))

4 More presentations in this session

Presentation thumbnail
Dapagliflozin utilization following hospitalization for heart failure: real-world insights from EVOLUTION HF, a multinational, observational study
Associate Professor G. Savarese (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Direct effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial
Doctor C. Andersen (Herlev, DK)
Abstract Slides
Presentation thumbnail
Acute effect of empagliflozin on serum uric acid - a subanalysis of the EMPAG-HF trial (effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure)
Mr J. Bogoviku (Jena, DE)
Abstract Slides
Presentation thumbnail
Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction - EMPEROR-Preserved trial
Professor M. Boehm (Homburg, DE)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - Pharmacotherapy

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources